高脂血症肾移植患者外周血MCP-1及其受体CCR2 mRNA表达及辛伐他汀治疗的影响

目的]探讨肾移植术后高脂血症患者外周血单核细胞趋化蛋白-1(MCP-1)及其受体CCR2 mRNA的表达及辛伐他汀治疗影响.方法]根据患者肾移植术后6个月的血脂水平,从167例肾移植受者中选择60例作为研究对象,其中30例为血脂正常组(A组),30例为血脂增高组(B组),健康体检者30例作为对照组,逆转录聚合酶链反应检测各组外周血MCP-1及CCR2 mRNA表达水平.血脂增高组给予辛伐他汀治疗,分别于1.5个月、3个月时复查血脂水平及MCP-1、CCR2 mRNA表达水平.结果]肾移植受者外周血MCP-1及其CCR2mRNA表达水平显著高于对照组,B组增高更为显著.辛伐他汀治疗1.5个月时,B组患者血脂水平及外周血MCP-1、CCR2 mRNA表达水平显著降低,3个月时进一步降低.结论]肾移植后高脂血症患者外周血MCP-1及CCR2 mRNA表达水平显著增高,可能参与了移植后心血管疾病及慢性移植肾排斥的发生.辛伐他汀治疗可显著降低肾移植受者外周血MCP-1及其CCR2 mRNA表达水平,此可能有助于减少或延缓移植后心血管疾病及慢性移植肾病的发生.

mRNA Expression of MCP-1 and Its Receptor CCR2 in Renal Transplant Recipients with Hyperlipidemia and Influence by Simvastatin Treatment

Objective] To investigate the mRNA expression of MCP-1 and CCR2 in peripheral blood monocyte cells of renal transplant recipients and the influence by Simvastatin treatment. Methods] Sixty recipients were selected from 167 renal transplant recipients, and were divided into two groups. Patients in Group A were without hyperlipidemia (n=30) and group B were with hyperlipidemia (n=30). Control group consists of 30 healthy volunteers. The patients in group B were treated with Simvastatin for 3 months. The mRNA expressions of MCP-1 and CCR2 were detected with RT-PCR. Results] The mRNA expressions of MCP-1 and CCR2 in post transplant recipients were significantly higher compared to normal controls, which were more evident in group B than those in group A. Serum hpid levels in the patients of group B decreased significantly after Simvastatin treatment. Meanwhile, the mRNA expression of MCP-1 and CCR2 reduced significantly at the 1.5th month of Simvastatin treatment, and reduced to a evidence even significantly lower than those in group A at the 3th month.Conclusions] It is suggested that upregulated expression of MCP-1 and CCR2 mRNA may be involved in the pathogenesis of CAN and CVD in renal transplant recipients with hyperlipidemia. Simvastatin might be used to reduce the mRNA expressions of MCP-1 and CCR2 in renal recipients with hyperhpidemia.